Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13006763 | 0.98 | MAPT (0.49) | KCNQ3KCNQ2MAPTUBE2TALDH1A1 | |
| SCHEMBL26739746 | 0.96 | MAPT (0.45) | KCNQ3KCNQ2MAPTUBE2TALDH1A1 | |
| SCHEMBL1619421 | 0.87 | RAB9A (0.52) | MAPTGAAKDM4ERAB9AL3MBTL1 | |
| SCHEMBL12845203 | 0.86 | RAB9A (0.57) | MAPTALDH1A1GAAKDM4ERAB9A | |
| SCHEMBL23446016 | 0.84 | CNR2 (0.46) | MAPTALDH1A1LMNACNR2GAA | |
| SCHEMBL2790485 | 0.84 | MAPT (0.58) | KCNQ3KCNQ2MAPTALDH1A1LMNA | |
| SCHEMBL24590407 | 0.83 | MAPT (0.55) | MAPTALDH1A1LMNAGAAKDM4E | |
| SCHEMBL15183915 | 0.82 | KDM4E (0.52) | MAPTALDH1A1GAAKDM4ERAB9A | |
| SCHEMBL26739734 | 0.82 | MAPT (0.43) | KCNQ3KCNQ2MAPTALDH1A1CNR2 | |
| SCHEMBL4082931 | 0.81 | KCNQ3 (0.48) | KCNQ3KCNQ2MAPTUBE2TALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057115-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008024746-A1 | 4-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| CN-115605477-B | Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof | 深圳众格生物科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-114181205-B | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| CN-115605477-A | Pyrazolo [1,5-a ] pyridine derivative and preparation method, composition and application thereof | 深圳众格生物科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-114181205-A | Pyrazolopyridine compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2018089904-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| WO-2010106333-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | KCNQ3 1048/4885KCNQ2 1997/4885MAPT 4568/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | KCNQ3 2050/4885KCNQ2 2842/4885MAPT 4671/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | KCNQ3 1375/4885KCNQ2 1849/4885MAPT 4795/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | KCNQ3 1510/4885KCNQ2 1970/4885MAPT 4795/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | KCNQ3 1105/4885KCNQ2 2051/4885MAPT 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.